Sign up to save your podcasts
Or
Share "Johnson & Johnson Surges on Strong Earnings and Institutional Backing"
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
"Johnson & Johnson Surges on Strong Earnings and Institutional Backing"
# Johnson & Johnson Stock Surges Near 52-Week Highs After Impressive Q3 Earnings
In this episode, we analyze Johnson & Johnson's impressive market performance, with shares trading near $191 and approaching yearly highs. We break down J&J's better-than-expected Q3 results, including adjusted earnings of $2.80 per share (up 15% YoY) and quarterly revenue reaching nearly $24 billion. Discover why major institutional investors, who control over 70% of shares, continue increasing their positions and why analysts from Raymond James, Wells Fargo, and Citigroup have raised price targets to between $209-$215 per share. We also examine the strategic implications of J&J's planned Orthopedics business separation and what the upcoming $1.30 quarterly dividend (2.7% yield) means for income-focused investors. Learn why this healthcare giant continues to attract strong institutional support even as market conditions remain challenging.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
In this episode, we analyze Johnson & Johnson's impressive market performance, with shares trading near $191 and approaching yearly highs. We break down J&J's better-than-expected Q3 results, including adjusted earnings of $2.80 per share (up 15% YoY) and quarterly revenue reaching nearly $24 billion. Discover why major institutional investors, who control over 70% of shares, continue increasing their positions and why analysts from Raymond James, Wells Fargo, and Citigroup have raised price targets to between $209-$215 per share. We also examine the strategic implications of J&J's planned Orthopedics business separation and what the upcoming $1.30 quarterly dividend (2.7% yield) means for income-focused investors. Learn why this healthcare giant continues to attract strong institutional support even as market conditions remain challenging.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
View all episodes
By Inception Point Ai# Johnson & Johnson Stock Surges Near 52-Week Highs After Impressive Q3 Earnings
In this episode, we analyze Johnson & Johnson's impressive market performance, with shares trading near $191 and approaching yearly highs. We break down J&J's better-than-expected Q3 results, including adjusted earnings of $2.80 per share (up 15% YoY) and quarterly revenue reaching nearly $24 billion. Discover why major institutional investors, who control over 70% of shares, continue increasing their positions and why analysts from Raymond James, Wells Fargo, and Citigroup have raised price targets to between $209-$215 per share. We also examine the strategic implications of J&J's planned Orthopedics business separation and what the upcoming $1.30 quarterly dividend (2.7% yield) means for income-focused investors. Learn why this healthcare giant continues to attract strong institutional support even as market conditions remain challenging.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
In this episode, we analyze Johnson & Johnson's impressive market performance, with shares trading near $191 and approaching yearly highs. We break down J&J's better-than-expected Q3 results, including adjusted earnings of $2.80 per share (up 15% YoY) and quarterly revenue reaching nearly $24 billion. Discover why major institutional investors, who control over 70% of shares, continue increasing their positions and why analysts from Raymond James, Wells Fargo, and Citigroup have raised price targets to between $209-$215 per share. We also examine the strategic implications of J&J's planned Orthopedics business separation and what the upcoming $1.30 quarterly dividend (2.7% yield) means for income-focused investors. Learn why this healthcare giant continues to attract strong institutional support even as market conditions remain challenging.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI